March 18 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* THE COVID-19 EFFECT ON XVIVO PERFUSION
* XVIVO PERFUSION SEES A DECLINE IN DEMAND FOR TRANSPLANT
PRODUCTS
DUE TO COVID-19 EPIDEMIC FOR AT LEAST NEXT QUARTER BUT SEES NO
LONG-TERM IMPACT ON DEMAND
* PLANNED START OF CLINICAL TRIALS IN EUROPE HAS BEEN
DELAYED
* AN ACTION PROGRAM IS NOW BEING IMPLEMENTED TO REDUCE
EXPENDITURE
* COMPANY ESTIMATES THAT SALES DURING Q1 WILL BE
APPROXIMATELY 15
PERCENT LESS THAN LAST YEAR
Source text for Eikon: ID:nWkr7MZYPm
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))